These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 21677472)

  • 1. Kidney cancer pathology in the new context of targeted therapy.
    Allory Y; Culine S; de la Taille A
    Pathobiology; 2011; 78(2):90-8. PubMed ID: 21677472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNAs Associated with Von Hippel-Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review.
    Schanza LM; Seles M; Stotz M; Fosselteder J; Hutterer GC; Pichler M; Stiegelbauer V
    Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29165391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PTEN suppression of YY1 induces HIF-2 activity in von-Hippel-Lindau-null renal-cell carcinoma.
    Petrella BL; Brinckerhoff CE
    Cancer Biol Ther; 2009 Jul; 8(14):1389-401. PubMed ID: 19483472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic profiling in renal cell carcinoma.
    Dizman N; Philip EJ; Pal SK
    Nat Rev Nephrol; 2020 Aug; 16(8):435-451. PubMed ID: 32561872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significance of PI3K signalling pathway in clear cell renal cell carcinoma in relation to VHL and HIF status.
    Tumkur Sitaram R; Landström M; Roos G; Ljungberg B
    J Clin Pathol; 2021 Apr; 74(4):216-222. PubMed ID: 32467322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tubulocystic renal cell carcinoma: is there a rational reason for targeted therapy using angiogenic inhibition? Analysis of seven cases.
    Steiner P; Hora M; Stehlik J; Martinek P; Vanecek T; Petersson F; Michal M; Korabecna M; Travnicek I; Hes O
    Virchows Arch; 2013 Feb; 462(2):183-92. PubMed ID: 23296808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Molecular tumor board-renal cell carcinoma].
    Grünwald V; Doehn C; Goebell PJ
    Urologe A; 2019 Jul; 58(7):768-773. PubMed ID: 31175376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
    Radulovic S; Bjelogrlic SK
    J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy.
    Clark PE
    Kidney Int; 2009 Nov; 76(9):939-45. PubMed ID: 19657325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal-cell carcinoma--molecular pathways and therapies.
    Brugarolas J
    N Engl J Med; 2007 Jan; 356(2):185-7. PubMed ID: 17215538
    [No Abstract]   [Full Text] [Related]  

  • 11. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
    Calvo E; Schmidinger M; Heng DY; Grünwald V; Escudier B
    Cancer Treat Rev; 2016 Nov; 50():109-117. PubMed ID: 27664394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.
    Choueiri TK; Vaziri SA; Jaeger E; Elson P; Wood L; Bhalla IP; Small EJ; Weinberg V; Sein N; Simko J; Golshayan AR; Sercia L; Zhou M; Waldman FM; Rini BI; Bukowski RM; Ganapathi R
    J Urol; 2008 Sep; 180(3):860-5; discussion 865-6. PubMed ID: 18635227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncotargets in different renal cancer subtypes.
    Moch H; Montironi R; Lopez-Beltran A; Cheng L; Mischo A
    Curr Drug Targets; 2015; 16(2):125-35. PubMed ID: 25619751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Current strategies in the treatment of renal-cell cancer: targeted therapies].
    Trigo JM; Bellmunt J
    Med Clin (Barc); 2008 Mar; 130(10):380-92. PubMed ID: 18381031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Papillary renal cell carcinoma: current progress and future directions.
    Twardowski PW; Mack PC; Lara PN
    Clin Genitourin Cancer; 2014 Apr; 12(2):74-9. PubMed ID: 24629521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecularly targeted therapy in renal cell carcinoma.
    Rathmell WK; Wright TM; Rini BI
    Expert Rev Anticancer Ther; 2005 Dec; 5(6):1031-40. PubMed ID: 16336094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Savolitinib for MET-driven papillary renal cell carcinoma.
    Gilbert JA
    Lancet Oncol; 2017 Aug; 18(8):e440. PubMed ID: 28669737
    [No Abstract]   [Full Text] [Related]  

  • 18. Targeted therapy for metastatic renal cell carcinoma.
    Motzer RJ; Bukowski RM
    J Clin Oncol; 2006 Dec; 24(35):5601-8. PubMed ID: 17158546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prospect of precision therapy for renal cell carcinoma.
    Ciccarese C; Brunelli M; Montironi R; Fiorentino M; Iacovelli R; Heng D; Tortora G; Massari F
    Cancer Treat Rev; 2016 Sep; 49():37-44. PubMed ID: 27453294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New drugs for metastatic kidney cancer].
    Doehn C
    Aktuelle Urol; 2008 Jan; 39(1):41-52. PubMed ID: 18228187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.